Antunes, LilianaMazagatos, ClaraMartínez-Baz, IvánGomez, VerónicaBorg, Maria-LouisePetrović, GorankaDuffy, RóisínDufrasne, François EDürrwald, RalfLazar, MihaelaJancoriene, LigitaOroszi, BeatrixHusa, PetrHoward, JenniferMelo, ArysePozo Sanchez, FranciscoPérez-Gimeno, GloriaCastilla, JesúsMachado, AusendaDžiugytė, AušraKarabuva, SvjetlanaFitzgerald, MargaretFierens, SébastienTolksdorf, KristinPopovici, Silvia-OdetteMickiene, AukseTúri, GergőSoučková, LenkaNicolay, NathalieRose, Angela McEuropean Hospital Vaccine Effectiveness Group2024-03-182024-03-182024-01Euro Surveill. 2024 Jan;29(3):2300708.http://hdl.handle.net/20.500.12105/18998We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.engVoRhttp://creativecommons.org/licenses/by/4.0/COVID-19COVID-19 bivalent vaccinesEuropeHospitalisationSARISARS-CoV-2Vaccine effectivenessXBBCOVID-19 VaccinesCOVID-19HumansCase-Control StudiesSARS-CoV-2HospitalizationEuropeRNA, MessengerEffectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023Atribución 4.0 Internacional38240061293230070810.2807/1560-7917.ES.2024.29.3.23007081560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access